PA8666701A1 - Nueva sal y polimorfos del inhibidor de la dpp-iv - Google Patents

Nueva sal y polimorfos del inhibidor de la dpp-iv

Info

Publication number
PA8666701A1
PA8666701A1 PA20068666701A PA8666701A PA8666701A1 PA 8666701 A1 PA8666701 A1 PA 8666701A1 PA 20068666701 A PA20068666701 A PA 20068666701A PA 8666701 A PA8666701 A PA 8666701A PA 8666701 A1 PA8666701 A1 PA 8666701A1
Authority
PA
Panama
Prior art keywords
polymorphes
dpp
inhibitor
new salt
thethylamino
Prior art date
Application number
PA20068666701A
Other languages
English (en)
Inventor
Andre Gerard Bubendorf
Michelangelo Scalone
Urs Schwitter
Stefan Abrecht
Stefan Goetzoe
Olaf Grassmann
Francois Montavon
Regina Moog
Franziska Rohrer
Armin Ruf
Shaoning Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8666701A1 publication Critical patent/PA8666701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCION SE REFIERE AL MESILATO DEL (S)-1-{[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETILAMINO-ACETIL}PIRROLIDINA-2-CARBONITRILO Y A POLIMORFOS CRISTALINOS DE ESTE COMPUESTO. ESTE COMPUESTO Y SUS FORMAS POLIMÓRFICAS POSEEN PROPIEDADES SUPERIORES SI SE COMPARAN CON LOS COMPUESTOS CONOCIDOS ANTERIORMENTE Y PUEDEN UTILIZARSE COMO MEDICAMENTOS PARA EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON LA DPP-IV.
PA20068666701A 2005-03-22 2006-03-21 Nueva sal y polimorfos del inhibidor de la dpp-iv PA8666701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102251 2005-03-22

Publications (1)

Publication Number Publication Date
PA8666701A1 true PA8666701A1 (es) 2006-12-07

Family

ID=36406081

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20068666701A PA8666701A1 (es) 2005-03-22 2006-03-21 Nueva sal y polimorfos del inhibidor de la dpp-iv

Country Status (17)

Country Link
US (1) US7772264B2 (es)
EP (1) EP1888571A2 (es)
JP (1) JP5043825B2 (es)
KR (1) KR20070113305A (es)
CN (1) CN101146801A (es)
AR (1) AR055570A1 (es)
AU (1) AU2006226447B2 (es)
BR (1) BRPI0609580A2 (es)
CA (1) CA2600203C (es)
DO (1) DOP2006000066A (es)
GT (1) GT200600125A (es)
IL (1) IL185768A0 (es)
MX (1) MX2007011546A (es)
PA (1) PA8666701A1 (es)
PE (1) PE20061109A1 (es)
TW (1) TW200700415A (es)
WO (1) WO2006100181A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
CZ2008512A3 (cs) 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CN106177958A (zh) 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103787944A (zh) * 2012-11-01 2014-05-14 天津药物研究院 1-(2-氯乙酰基)-2-(s)-腈基吡咯烷的制备方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN104262227B (zh) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN106699627A (zh) * 2016-12-29 2017-05-24 青岛黄海制药有限责任公司 一种多相复式非连续生产法制备1‑(2‑氯乙酰基)‑2‑(s)‑氰基吡咯烷的方法
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07247246A (ja) * 1994-03-09 1995-09-26 Daicel Chem Ind Ltd １−フェニル−３−ブチン誘導体とその製造方法
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ATE212635T1 (de) * 1997-12-05 2002-02-15 1,3,8-triazaspiro(4,5)decan-4-on-derivate
DE19755436A1 (de) 1997-12-13 1999-06-24 Beiersdorf Ag Verfahren zur zumindest partiellen direkten Beschichtung eines dehnfähigen Trägermaterials mit einer Haftklebemasse
CN1235887C (zh) * 1998-03-30 2006-01-11 日本烟草产业株式会社 噁唑基乙醇衍生物的制备方法
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
ZA200501418B (en) * 2002-08-29 2006-10-25 Taisho Pharmaceutical Co Ltd Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process

Also Published As

Publication number Publication date
CA2600203A1 (en) 2006-09-28
AU2006226447B2 (en) 2009-07-16
JP2008534470A (ja) 2008-08-28
TW200700415A (en) 2007-01-01
BRPI0609580A2 (pt) 2010-04-20
PE20061109A1 (es) 2006-10-13
KR20070113305A (ko) 2007-11-28
CA2600203C (en) 2012-12-04
DOP2006000066A (es) 2006-09-30
IL185768A0 (en) 2008-01-06
US20060217428A1 (en) 2006-09-28
MX2007011546A (es) 2007-10-19
US7772264B2 (en) 2010-08-10
WO2006100181A2 (en) 2006-09-28
JP5043825B2 (ja) 2012-10-10
CN101146801A (zh) 2008-03-19
EP1888571A2 (en) 2008-02-20
GT200600125A (es) 2007-03-16
AR055570A1 (es) 2007-08-22
AU2006226447A1 (en) 2006-09-28
WO2006100181A3 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
PA8666701A1 (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
UY32730A (es) Inhibidores de cyp17
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
NI201100049A (es) Compuestos orgánicos.
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
BRPI0821102A2 (pt) Preparação de derivados de di-hidropirrol como intermediários
TN2010000038A1 (en) Organic compounds
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
UY31824A (es) Nuevos compuestos
NI201100035A (es) Agentes antifúngicos.
GT200900037A (es) Compuestos organicos
ATE481395T1 (de) Cyclohexylderivate
SV2009003315A (es) Nueva utilizacion para el tratamiento de las leucemias